{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:35Z","timestamp":1760060495612,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CONAHCyT","award":["F003: C-52-2021","F003: 321211","PRONAII: 303081","PRONAII: 302965"],"award-info":[{"award-number":["F003: C-52-2021","F003: 321211","PRONAII: 303081","PRONAII: 302965"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Replication-defective adenoviruses are widely used as vectors for vaccines, but their efficacy may be compromised by the prevalence of pre-existing neutralizing antibodies from natural infections or prior vaccination with adenovirus-based vaccines. To overcome these limitations, less common human adenovirus (HAdV) types and simian adenoviruses (SAdV) have been explored as alternative vectors to the widely prevalent HAdV-C5. Despite their importance, there is limited information on the epidemiology of adenovirus immunity in many countries and geographical regions, including Mexico. In this study, we analyzed 2488 serum samples from healthy adults across all 32 states of Mexico to assess the prevalence of both total and neutralizing antibodies against various HAdV types from species A-F, and three related SAdVs. Our findings indicate a high prevalence of neutralizing antibodies against HAdV-C5 and HAdV-C6, with significant cross-reactivity observed among related adenoviruses. Notably, HAdV-D26 exhibited a lower prevalence of neutralizing antibodies, suggesting its potential suitability as a vector for vaccine development in populations with high pre-existing immunity to more common HAdV types. These results provide critical insights for optimizing adenovirus-based vaccine strategies in Mexico.<\/jats:p>","DOI":"10.3390\/v17091184","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:18:15Z","timestamp":1756484295000},"page":"1184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seroprevalence of Neutralizing Antibodies in Healthy Adults, in Mexico, Against Human and Simian Adenovirus Types"],"prefix":"10.3390","volume":"17","author":[{"given":"Ra\u00fal E.","family":"L\u00f3pez","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n en Din\u00e1mica Celular, Instituto de Investigaci\u00f3n en Ciencias B\u00e1sicas y Aplicadas, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"},{"name":"Laboratorio Nacional de Vacunolog\u00eda y Virus Tropicales, Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico 11340, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-128X","authenticated-orcid":false,"given":"Margarita","family":"Vald\u00e9s Alem\u00e1n","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Din\u00e1mica Celular, Instituto de Investigaci\u00f3n en Ciencias B\u00e1sicas y Aplicadas, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2194-521X","authenticated-orcid":false,"given":"Jes\u00fas M.","family":"Torres-Flores","sequence":"additional","affiliation":[{"name":"Laboratorio Nacional de Vacunolog\u00eda y Virus Tropicales, Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico 11340, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yordanis","family":"P\u00e9rez-Llano","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Din\u00e1mica Celular, Instituto de Investigaci\u00f3n en Ciencias B\u00e1sicas y Aplicadas, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5314-4786","authenticated-orcid":false,"given":"David Alejandro","family":"Cabrera Gayt\u00e1n","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Esperanza","family":"Santacruz Tinoco","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-9045","authenticated-orcid":false,"given":"Julio Elias","family":"Alvarado Yaah","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Mei","family":"Anguiano Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Mart\u00ednez Miguel","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1289-4457","authenticated-orcid":false,"given":"Jos\u00e9 Esteban","family":"Mu\u00f1oz Medina","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Sandoval Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico 07760, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse Ramos","family":"Lagunes","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n T\u00e9cnica y de Investigaci\u00f3n, Centro Nacional de la Transfusi\u00f3n Sangu\u00ednea, Ciudad de M\u00e9xico 17360, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Arroyo P\u00e9rez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n T\u00e9cnica y de Investigaci\u00f3n, Centro Nacional de la Transfusi\u00f3n Sangu\u00ednea, Ciudad de M\u00e9xico 17360, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-8529","authenticated-orcid":false,"given":"Ram\u00f3n A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Din\u00e1mica Celular, Instituto de Investigaci\u00f3n en Ciencias B\u00e1sicas y Aplicadas, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Khanal, S., Ghimire, P., and Dhamoon, A.S. (2018). The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly. Biomedicines, 6.","DOI":"10.20944\/preprints201801.0267.v1"},{"key":"ref_2","unstructured":"Fields, B.N., Knipe, D.M., and Howley, P.M. (2007). Fields Virology, Wolters Kluwer Health\/Lippincott Williams & Wilkins."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/mthe.2000.0032","article-title":"Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX","volume":"1","author":"Fields","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/jvi.54.3.711-719.1985","article-title":"Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome","volume":"54","author":"Saito","year":"1985","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1073\/pnas.82.11.3567","article-title":"Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector","volume":"82","author":"Yamada","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/jvi.57.1.267-274.1986","article-title":"Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene","volume":"57","author":"Graham","year":"1986","journal-title":"J. Virol."},{"key":"ref_9","first-page":"2872","article-title":"Construction of a Helper-Free Recombinant Adenovirus That Expresses Polyomavirus Large T Antigen","volume":"6","author":"Massie","year":"1986","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","first-page":"1145","article-title":"Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection","volume":"32","author":"Tomita","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2014friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/erv.09.29","article-title":"Strategies to overcome host immunity to adenovirus vectors in vaccine development","volume":"8","author":"Thacker","year":"2009","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omto.2022.03.007","article-title":"Development of a low-seroprevalence, \u03b1v\u03b26 integrin-selective virotherapy based on human adenovirus type 10","volume":"25","author":"Bates","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e0038721","DOI":"10.1128\/JVI.00387-21","article-title":"Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development","volume":"95","author":"Ballmann","year":"2021","journal-title":"J. Virol."},{"key":"ref_18","unstructured":"Mexican Government (2025, February 03). Vacunas COVID-19 Autorizadas. Available online: https:\/\/www.gob.mx\/cofepris\/acciones-y-programas\/vacunas-covid-19-autorizadas."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1542\/peds.101.6.1013","article-title":"Incidence and Prevalence of Neutralizing Antibodies to the Common Adenoviruses in Children with Cystic Fibrosis: Implication for Gene Therapy with Adenovirus Vectors","volume":"101","author":"Piedra","year":"1998","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1099\/jgv.0.000978","article-title":"Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56","volume":"99","author":"Duffy","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF01780642","article-title":"Adenovirus infection in cystic fibrosis patients: Implications for the use of adenoviral vectors for gene transfer","volume":"24","author":"Rosenecker","year":"1996","journal-title":"Infection"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1099\/vir.0.82079-0","article-title":"Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity","volume":"87","author":"Lemckert","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: Design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ludert, J.E., Pujol, F.H., and Arbiza, J. (2017). Human Virology in Latin America: From Biology to Control, Springer International Publishing.","DOI":"10.1007\/978-3-319-54567-7"},{"key":"ref_31","first-page":"29","article-title":"Construction of adenovirus type 5 early region 1 and 4 virus mutants","volume":"130","author":"Groitl","year":"2007","journal-title":"Methods Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Schmidt, U., Weigert, M., Broaddus, C., and Myers, G. (2018). Cell Detection with Star-Convex Polygons 2018, Springer International Publishing.","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wickham, H. (2016). Ggplot2: Elegant Graphics for Data Analysis, Springer International Publishing.","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"ref_34","unstructured":"Kolde, R. (2025, February 03). Pheatmap: Pretty Heatmaps. Available online: https:\/\/cran.r-project.org\/web\/packages\/pheatmap\/pheatmap.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/bioinformatics\/btv494","article-title":"Msa: An R package for multiple sequence alignment","volume":"31","author":"Bodenhofer","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_36","unstructured":"Bastolla, U., Porto, M., Roman, H.E., and Vendruscolo, M. (2007). SeqinR 1.0-2: A Contributed Package to the R Project for Statistical Computing Devoted to Biological Sequences Retrieval and Analysis. Structural Approaches to Sequence Evolution: Molecules, Networks, Populations, Springer."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/bioinformatics\/btg412","article-title":"APE: Analyses of Phylogenetics and Evolution in R language","volume":"20","author":"Paradis","year":"2004","journal-title":"Bioinformatics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/2041-210X.12628","article-title":"Ggtree: An R package for visualization and annotation of phylogenetic trees with their covariates and other associated data","volume":"8","author":"Yu","year":"2017","journal-title":"Methods Ecol. Evol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-023-00805-6","article-title":"Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum","volume":"25","author":"Dai","year":"2023","journal-title":"AAPS J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.virusres.2018.08.007","article-title":"Identification of adenovirus neutralizing antigens using capsid chimeric viruses","volume":"256","author":"Liu","year":"2018","journal-title":"Virus Research"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1016\/j.vaccine.2009.06.041","article-title":"Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein","volume":"27","author":"Yuan","year":"2009","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1016\/j.vaccine.2015.10.117","article-title":"Neutralizing epitopes mapping of human adenovirus type 14 hexon","volume":"33","author":"Ma","year":"2015","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2018.01.005","article-title":"In silico identification of potential epitopes present in human adenovirus proteins for vaccine design and of putative drugs for treatment against viral infection","volume":"455","author":"Hossain","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1016\/j.vaccine.2021.05.023","article-title":"Identification of potent epitopes on hexon capsid protein and their evaluation as vaccine candidates against infections caused by members of Adenoviridae family","volume":"39","author":"Tufail","year":"2021","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.virol.2018.03.002","article-title":"Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity","volume":"518","author":"Feng","year":"2018","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.07076-11","article-title":"Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions","volume":"86","author":"Qiu","year":"2012","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1016\/j.vaccine.2016.09.043","article-title":"Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions","volume":"34","author":"Yang","year":"2016","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ye, X., Xiao, L., Zheng, X., Wang, J., Shu, T., Feng, Y., Liu, X., Su, W., Wang, Q., and Li, C. (2018). Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations From Southern China. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.03040"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12250-020-00307-1","article-title":"Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China","volume":"36","author":"Tian","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/CVI.00173-07","article-title":"Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: Implications for recombinant adenovirus-based vaccines","volume":"14","author":"Appaiahgari","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/jmv.27473","article-title":"Seroprevalence and molecular characterization of human respiratory syncytial virus and human adenovirus among children in Ado-Ekiti, Nigeria","volume":"94","author":"Idris","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ouoba, A.R., Paris, O., Adawaye, C., Dzomo, G.T., Fouda, A.A., Kania, D., Diarra, A., Kallo, Z.A., Traore, I.T., and Sirima, S.B. (2022). Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad. medRxiv, preprint.","DOI":"10.1101\/2022.06.07.22276076"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/trf.15415","article-title":"Sociodemographic and behavioral characteristics associated with blood donation in the United States: A population-based study","volume":"59","author":"Patel","year":"2019","journal-title":"Transfusion"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ma, M., Yang, R., Gu, J., Ke, S., Du, X., and Zheng, J. (2024). Factors associated with blood donation among college and university students in Wuhan, China: Structural equation model. BMC Public Health, 24.","DOI":"10.1186\/s12889-024-19384-y"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Feng, W., Yun, W., Le, W., Zhi-Guo, X., Hai-Ying, Y., Shu-Fang, W., Zhen-Yan, W., Yi-Zhu, C., Quan, S., and Jing-Xian, F. (2023). The influence of demographic and lifestyle factors on blood donation delay among student population: A retrospective study. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1297472"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0974-2700.58667","article-title":"Analyzing sociodemographic factors amongst blood donors","volume":"3","author":"Shenga","year":"2010","journal-title":"J. Emerg. Trauma Shock"},{"key":"ref_57","first-page":"e60688","article-title":"Sociodemographic Profile of Blood Donations and Ways to Encourage Them","volume":"16","year":"2024","journal-title":"Cureus"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhao, H., Xu, C., Luo, X., Wei, F., Wang, N., Shi, H., and Ren, X. (2018). Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00335"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Dehghan, S., Seto, J., Liu, E.B., Ismail, A.M., Madupu, R., Heim, A., Jones, M.S., Dyer, D.W., Chodosh, J., and Seto, D.A. (2019). Zoonotic Adenoviral Human Pathogen Emerged through Genomic Recombination among Human and Nonhuman Simian Hosts. J. Virol., 93.","DOI":"10.1128\/JVI.00564-19"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, E.C., Yagi, S., Kelly, K.R., Mendoza, S.P., Maninger, N., Rosenthal, A., Spinner, A., Bales, K.L., Schnurr, D.P., and Lerche, N.W. (2011). Correction: Cross-Species Transmission of a Novel Adenovirus Associated with a Fulminant Pneumonia Outbreak in a New World Monkey Colony. PLOS Pathog., 7.","DOI":"10.1371\/annotation\/59703f7f-9506-49d1-b339-09ee31510e89"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:37Z","timestamp":1760034937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["v17091184"],"URL":"https:\/\/doi.org\/10.3390\/v17091184","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}